```
=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 10:22:56 ON 14 AUG 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 14 Aug 2010  VOL 153 ISS 8
FILE LAST UPDATED: 13 Aug 2010  (20100813/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d stat que l24
L1              STR
```




```
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  12

STEREO ATTRIBUTES: NONE
L3       173813 SEA FILE=REGISTRY SSS FUL L1
```

L8 STR



VAR G1=5/7/9/11/16/19/CN/NO/OH/SH
VAR G2=21/22/23/24/26
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 27 25
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
L15 7677 SEA FILE=REGISTRY SUB=L3 SSS FUL L8
L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

L18 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L19 1520 SEA FILE=REGISTRY SUB=L15 SSS FUL L8 NOT (L16 OR L18)
L20 STR

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 2
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 3

STEREO ATTRIBUTES: NONE
L21 338 SEA FILE=REGISTRY SUB=L19 SSS FUL L20
L22 104 SEA FILE=HCAPLUS ABB=ON PLU=ON L21
L23 86 SEA FILE=HCAPLUS ABB=ON PLU=ON L22 AND (AY=<2006 OR PY=<2006 OR PRY=<2006 OR PD=<JUNE 8, 2006)
L24 12 SEA FILE=HCAPLUS ABB=ON PLU=ON L23 AND (?DRUG? OR ?PHARM? OR ?MEDIC? OR ?THERAP?)

=> d ibib abs hitstr l24 1-12

L24 ANSWER 1 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:636821 HCAPLUS Full-text
DOCUMENT NUMBER: 145:103712
TITLE: Preparation of pyrimidine-based inhibitors of dipeptidyl peptidase IV
INVENTOR(S): Meng, Wei; Hamann, Lawrence G.; Brigance, Robert
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20060142576 | A1 | 20060629 | US 2005-314795 | 20051221 <-- |
| US 7589088 | B2 | 20090915 | | |
| WO 2006071762 | A2 | 20060706 | WO 2005-US46750 | 20051223 <-- |
| WO 2006071762 | A3 | 20061123 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | |
| EP 1831180 | A2 | 20070912 | EP 2005-855333 | 20051223 <-- |
| R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | | | | |

PRIORITY APPLN. INFO.: US 2004-640110P P 20041229 <--
WO 2005-US46750 W 20051223 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:103712; MARPAT 145:103712
GI




I II

AB The title compds. I [n = 1-2; R = H, halo, CN, etc.; B = a bond, O, N, SOm; m = 0-2; X = H, alkyl, cycloalkyl, aryl, etc.; BX taken together can be a halogen; Y = (un)substituted aryl], useful as DPP-4 inhibitors, were prepared E.g., a multistep synthesis of I, starting from 2,4-dichlorobenzoyl chloride, was given. In general, exemplified compds. I have been identified to inhibit the catalytic activity of dipeptidyl peptidase IV at concns. equivalent to, or more potently than, 10 μM,

preferably 5 μM, more preferably 3 μM (no specific data given). Pharmaceutical composition comprising the compound I alone or in combination with other therapeutic agents are disclosed.

IT 895151-42-5P 895151-47-0P 895151-54-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrimidine-based dipeptidyl peptidase IV inhibitors)

RN 895151-42-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(2,4-dichlorophenyl)-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 895151-47-0 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(2,4-dichlorophenyl)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 895151-54-9 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(4-chloro-2-methylphenyl)-2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 100 THERE ARE 100 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:451367 HCAPLUS Full-text
DOCUMENT NUMBER: 142:476293

TITLE: Substituted pyrimidine compositions and methods using them for the treatment of NGFI-B-related diseases
INVENTOR(S): Martin, Richard; Mohan, Raju; Ordentlich, Peter
PATENT ASSIGNEE(S): X-Ceptor Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 117 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005047268 | A2 | 20050526 | WO 2004-US37642 | 20041109 <-- |
| WO 2005047268 | A3 | 20050721 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | |
| RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| US 20070293464 | A1 | 20071220 | US 2007-595734 | 20070522 <-- |
| PRIORITY APPLN. INFO.: | | | US 2003-519030P P | 20031110 <-- |
| | | | WO 2004-US37642 W | 20041109 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 142:476293
AB Compns. and methods using substituted pyrimidines are provided. The substituted pyrimidines may be used to treat diseases modulated by NGFI-B family activity.
IT 320418-43-7 320418-48-2 320418-49-3
338395-36-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrimidine derivs. for treatment of NGFI-B-related diseases)
RN 320418-43-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 2,4-diphenyl-6-(phenylthio)- (CA INDEX NAME)




RN 320418-48-2 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-2-phenyl-6-(phenylthio)- (CA INDEX NAME)



RN 320418-49-3 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-6-[(4-chlorophenyl)thio]-2-phenyl- (CA INDEX NAME)



RN 338395-36-1 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(4-methoxyphenyl)-2-phenyl-6-(phenylthio)- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:395283 HCAPLUS Full-text
DOCUMENT NUMBER: 142:463736
TITLE: Preparation of pyrimidine derivatives as IKK-2 inhibitors
INVENTOR(S): Clare, Michael; Hagen, Timothy J.; Houdek, Stephen C.; Lennon, Patrick J.; Weier, Richard M.; Xu, Xiangdong
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2005040133 | A1 | 20050506 | WO 2004-IB3314 | 20041011 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

| | | | | | |
|---|---|---|---|---|---|
| CA 2542514 | A1 | 20050506 | CA 2004-2542514 | 20041011 | <-- |
| EP 1678146 | A1 | 20060712 | EP 2004-769607 | 20041011 | <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK | | | | | |
| BR 2004015678 | A | 20061219 | BR 2004-15678 | 20041011 | <-- |
| JP 2007509126 | T | 20070412 | JP 2006-536194 | 20041011 | <-- |
| MX 2006004498 | A | 20060620 | MX 2006-4498 | 20060421 | <-- |
| PRIORITY APPLN. INFO.: | | | US 2003-513770P P | 20031023 | <-- |
| | | | WO 2004-IB3314 W | 20041011 | <-- |

OTHER SOURCE(S): CASREACT 142:463736; MARPAT 142:463736

GI


I




II

AB Title compds. I [A = cycloalkyl, aryl, heterocycloalkyl, etc.; X = substituted aryl with substituents selected from CN, NO2, OH, etc.; R1 = CN, CO2R3, CH2OR3, etc.; R2 = NR4R5; R3 = OH, alkoxy, alkyl, etc.; R4 and R5 independently = aryl, heteroaryl, haloalkyl, etc.] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of IKK-2. Thus, e.g., II was prepared in a multi-step synthesis from 2,6-dibenzyloxybenzonitrile. The activity of I was evaluated in IKK-2 inhibition assays and it revealed IC50 values for selected compds. of the invention in the range of 0.438 up to 24.4 μM. I as inhibitor of IKK-2 should prove useful in the treatment of inflammation, cancer or an inflammation-associated disorder.

IT 851382-51-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrimidine derivs. as IKK-2 inhibitors)
RN 851382-51-9 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-(2-hydroxyphenyl)-6-(3-methoxyphenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:394829 HCAPLUS Full-text
DOCUMENT NUMBER: 142:463605
TITLE: Preparation aryloxyacetic acids and related compounds as PPARδ and PPARα agonists
INVENTOR(S): Ackermann, Jean; Aebi, Johannes; Binggeli, Alfred; Grether, Uwe; Hirth, Georges; Kuhn, Bernd; Maerki, Hans-Peter; Meyer, Markus; Mohr, Peter; Wright, Matthew Blake
PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 20050096337 | A1 | 20050505 | US 2004-978155 | 20041029 <-- |
| US 7115611 | B2 | 20061003 | | |
| AU 2004291262 | A1 | 20050602 | AU 2004-291262 | 20041028 <-- |
| CA 2543249 | A1 | 20050602 | CA 2004-2543249 | 20041028 <-- |
| WO 2005049573 | A1 | 20050602 | WO 2004-EP12217 | 20041028 <-- |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

| | | | | | |
|---|---|---|---|---|---|
| | SN, TD, TG | | | | |
| EP 1682508 | A1 | 20060726 | EP 2004-790987 | 20041028 | <-- |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR | | | | | |
| CN 1875002 | A | 20061206 | CN 2004-80032273 | 20041028 | <-- |
| BR 2004016283 | A | 20070123 | BR 2004-16283 | 20041028 | <-- |
| JP 2007509999 | T | 20070419 | JP 2006-538711 | 20041028 | <-- |
| NZ 546444 | A | 20090925 | NZ 2004-546444 | 20041028 | <-- |
| RU 2374230 | C2 | 20091127 | RU 2006-119510 | 20041028 | <-- |
| AR 46924 | A1 | 20060104 | AR 2004-104043 | 20041103 | <-- |
| TW 259179 | B | 20060801 | TW 2004-93133654 | 20041104 | <-- |
| MX 2006004641 | A | 20060627 | MX 2006-4641 | 20060426 | <-- |
| ZA 2006003531 | A | 20070725 | ZA 2006-3531 | 20060503 | <-- |
| KR 2006086373 | A | 20060731 | KR 2006-708742 | 20060504 | <-- |
| KR 847976 | B1 | 20080722 | | | |
| NO 2006002135 | A | 20060524 | NO 2006-2135 | 20060512 | <-- |
| KR 2008042188 | A | 20080514 | KR 2008-710674 | 20080502 | <-- |
| PRIORITY APPLN. INFO.: | | | EP 2003-104081 | A 20031105 | <-- |
| | | | EP 2004-100759 | A 20040226 | <-- |
| | | | WO 2004-EP12217 | W 20041028 | <-- |
| | | | KR 2006-708742 | A3 20060504 | <-- |

OTHER SOURCE(S): MARPAT 142:463605

GI



I



II

AB Title compds. I [X = O, S, CH2; R1 = H, alkyl; R2 = H, alkyl with provisos; R3 = H, alkyl; R4, R8 = H, alkyl, cycloalkyl, etc.; R5, R6, R7 = H, alkyl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, saponification of Et ester II (Z = OEt), afforded acid II (Z = OH) as a light yellow solid. In PPARα receptor binding assays, 3-examples of compds. I exhibited IC50 values ranging from 0.013-0.289 μmol/l. Compds. I are claimed to be useful for the treatment of diseases modulated by PPARδ and PPARα agonist.

IT 851507-67-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation aryloxyacetic acids and related compds. as PPARδ and

PPARα agonists)
RN 851507-67-0 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-cyclopropyl-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2004:189163 HCAPLUS Full-text
DOCUMENT NUMBER: 140:399337
TITLE: Aminomethylpyrimidines as novel DPP-IV inhibitors: A 100 000-fold activity increase by optimization of aromatic substituents
AUTHOR(S): Peters, Jens-Uwe; Weber, Silja; Kritter, Stephane; Weiss, Peter; Wallier, Angelina; Boehringer, Markus; Hennig, Michael; Kuhn, Bernd; Loeffler, Bernd-Michael
CORPORATE SOURCE: Pharma Division, Preclinical Research, F. Hoffmann-La Roche Ltd., Basel, CH-4070, Switz.
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(6), 1491-1493
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 140:399337
AB The influence of aromatic substitution on a newly discovered class of inhibitors of dipeptidyl peptidase IV was investigated. A 100,000-fold increase in potency was achieved by the optimization of aromatic substituents in a parallel chemical program. The observed SAR could be explained by an x-ray structure of the protein-ligand complex.
IT 20954-77-2P 115071-95-9P 475995-38-1P
475995-39-2P 475995-40-5P 582306-94-3P
582306-95-4P 582306-96-5P 582306-97-6P
582306-98-7P 582306-99-8P 582307-01-5P
761357-05-5P 870452-74-7P 870452-77-0P
870452-90-7P 870452-93-0P 870452-97-4P
870454-17-4P 870455-34-8P 870455-77-9P
870456-89-6P 870456-91-0P 870457-11-7P
870457-13-9P 870457-26-4P 870457-52-6P
870457-86-6P 870458-05-2P 870458-54-1P
870458-83-6P 870458-84-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(synthesis and activity of aminomethylpyrimidines as novel DPP-IV inhibitors)
RN 20954-77-2 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2,6-diphenyl- (CA INDEX NAME)



RN 115071-95-9 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(4-chlorophenyl)-2-phenyl- (CA INDEX NAME)



RN 475995-38-1 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(4-fluorophenyl)-2-phenyl- (CA INDEX NAME)



RN 475995-39-2 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 475995-40-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-94-3 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-phenyl-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 582306-95-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-96-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(3-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-97-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(3-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-98-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-99-8 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3-methoxyphenyl)- (CA INDEX NAME)



RN 582307-01-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 761357-05-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(4-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 870452-74-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2-chlorophenyl)-2-phenyl- (CA INDEX NAME)



RN 870452-77-0 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(3-chlorophenyl)-2-phenyl- (CA INDEX NAME)



RN 870452-90-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 870452-93-0 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2-fluorophenyl)-2-phenyl- (CA INDEX NAME)



RN 870452-97-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(3-fluorophenyl)-2-phenyl- (CA INDEX NAME)



RN 870454-17-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-phenyl-6-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 870455-34-8 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-phenyl-6-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 870455-77-9 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(2-methylphenyl)- (CA INDEX NAME)



RN 870456-89-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(4-methylphenyl)- (CA INDEX NAME)



RN 870456-91-0 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-(3-chlorophenyl)-6-(2,4-dichlorophenyl)- (CA INDEX NAME)



RN 870457-11-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-2-(4-chlorophenyl)-6-(2,4-dichlorophenyl)- (CA INDEX NAME)



RN 870457-13-9 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(2-methoxyphenyl)- (CA INDEX NAME)



RN 870457-26-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(2-fluorophenyl)- (CA INDEX NAME)



RN 870457-52-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3-fluorophenyl)- (CA INDEX NAME)



RN 870457-86-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(4-fluorophenyl)- (CA INDEX NAME)



RN 870458-05-2 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 870458-54-1 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 870458-83-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3,4-difluorophenyl)- (CA INDEX NAME)



RN 870458-84-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3,5-dimethoxyphenyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 31 THERE ARE 31 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:202645 HCAPLUS Full-text
DOCUMENT NUMBER: 138:238195
TITLE: Preparation of glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity
INVENTOR(S): Hanssen, Robert Gerard Jules Marie; Timmers, Cornelis Marius; Kelder, Jan
PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003020727 | A1 | 20030313 | WO 2002-EP9648 | 20020829 <-- |
| W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2457212 | A1 | 20030313 | CA 2002-2457212 | 20020829 <-- |
| AU 2002333750 | A1 | 20030318 | AU 2002-333750 | 20020829 <-- |
| AU 2002333750 | B2 | 20080221 | | |
| EP 1427734 | A1 | 20040616 | EP 2002-797646 | 20020829 <-- |
| EP 1427734 | B1 | 20051109 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK | | | | |
| BR 2002012173 | A | 20040720 | BR 2002-12173 | 20020829 <-- |
| HU 2004001443 | A2 | 20041129 | HU 2004-1443 | 20020829 <-- |

| | | | | | |
|---|---|---|---|---|---|
| HU 2004001443 | A3 | 20080528 | | | |
| CN 1551883 | A | 20041201 | CN 2002-817240 | 20020829 | <-- |
| CN 1261437 | C | 20060628 | | | |
| JP 2005504784 | T | 20050217 | JP 2003-524997 | 20020829 | <-- |
| JP 4263094 | B2 | 20090513 | | | |
| NZ 531375 | A | 20050624 | NZ 2002-531375 | 20020829 | <-- |
| AT 309251 | T | 20051115 | AT 2002-797646 | 20020829 | <-- |
| ES 2252540 | T3 | 20060516 | ES 2002-797646 | 20020829 | <-- |
| RU 2294331 | C2 | 20070227 | RU 2004-110036 | 20020829 | <-- |
| IL 160194 | A | 20090615 | IL 2002-160194 | 20020829 | <-- |
| ZA 2004001459 | A | 20041122 | ZA 2004-1459 | 20040223 | <-- |
| HR 2004000194 | A2 | 20040831 | HR 2004-194 | 20040226 | <-- |
| US 20040180907 | A1 | 20040916 | US 2004-488483 | 20040226 | <-- |
| US 7375109 | B2 | 20080520 | | | |
| KR 891630 | B1 | 20090403 | KR 2004-703096 | 20040302 | <-- |
| MX 2004002046 | A | 20040716 | MX 2004-2046 | 20040303 | <-- |
| IN 2004CN00468 | A | 20051223 | IN 2004-CN468 | 20040304 | <-- |
| IN 213079 | A1 | 20080328 | | | |
| PRIORITY APPLN. INFO.: | | | EP 2001-203328 A | 20010904 | <-- |
| | | | WO 2002-EP9648 W | 20020829 | <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 138:238195

GI



I

AB The title compds. [I; X = 0 or H,H; A = S, NH, NR6, 0, a bond; R1 = alkyl, alkenyl, (un)substituted Ph, heteroaryl; R2 = H, alkyl, alkoxyalkyl, hydroxyalkyl; R3, R4 = H, alkyl, hydroxyalkyl; R5 = H, alkyl; R6 can be selected from the same groups as described for R1] which have LH as well as FSH receptor activating activity and can be used in fertility regulating therapies, were prepared E.g., a 9-step synthesis of I.TFA [X = H,H; A = S; R1, R2 = Me; R3-R5 = H], starting from S-methylisothiourea sulfate, 3-nitrobenzaldehyde and Et cyanoacetate, was given. All twenty-six exemplified compds. I were tested for LH/FSH in vitro and in vivo bioactivity and data were given.

IT 405891-46-5P, 6-Chloro-5-cyano-4-(3-nitrophenyl)-2-phenylpyrimidine 405891-47-6P, 5-Cyano-4-(3-nitrophenyl)-2-phenyl-6-(ethoxycarbonylmethylthio)pyrimidine
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of glycine-substituted thieno[2,3-d]pyrimidines with combined LH and FSH agonistic activity)

RN 405891-46-5 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-chloro-6-(3-nitrophenyl)-2-phenyl- (CA INDEX NAME)



RN 405891-47-6 HCAPLUS
CN Acetic acid, 2-[[5-cyano-6-(3-nitrophenyl)-2-phenyl-4-pyrimidinyl]thio]-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:174482 HCAPLUS Full-text
DOCUMENT NUMBER: 138:198678
TITLE: Small-molecule modulators of hepatocyte growth factor/scatter factor activities as drugs
INVENTOR(S): Pillarisetti, Sivaram; Goldberg, Itzhak D.
PATENT ASSIGNEE(S): North Shore-Long Island Jewish Health System, USA
SOURCE: U.S. Pat. Appl. Publ., 37 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE | |
|---|---|---|---|---|---|
| US 20030045559 | A1 | 20030306 | US 2001-896832 | 20010629 | <-- |
| US 6589997 | B2 | 20030708 | | | |
| US 20030022924 | A1 | 20030130 | US 2001-26672 | 20011219 | <-- |
| US 6610726 | B2 | 20030826 | | | |
| US 20030216459 | A1 | 20031120 | US 2003-456326 | 20030606 | <-- |
| US 6855728 | B2 | 20050215 | | | |
| US 20050096372 | A1 | 20050505 | US 2004-7333 | 20041208 | <-- |
| PRIORITY APPLN. INFO.: | | | US 2001-896832 | A2 20010629 | <-- |
| | | | US 2003-456326 | A3 20030606 | <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 138:198678
AB The invention is directed to small organic mols. having the ability to mimic or agonize hepatocyte growth factor/scatter factor (HGF/SF) activity, or inhibit or

antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer. Pharmaceutical compns. containing the modulators are also claimed.

IT 320417-50-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(small-mol. modulators of hepatocyte growth factor/scatter factor activities as drugs)

RN 320417-50-3 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-6-(dimethylamino)-2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 8 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:31482 HCAPLUS Full-text
DOCUMENT NUMBER: 136:79802
TITLE: Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
INVENTOR(S): Pillarisetti, Sivaram; Goldberg, Itzhak D.
PATENT ASSIGNEE(S): North Shore-Long Island Jewish Health System, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002002593 | A2 | 20020110 | WO 2001-US20849 | 20010629 <-- |
| WO 2002002593 | A3 | 20030807 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2452445 | A1 | 20020110 | CA 2001-2452445 | 20010629 <-- |
| EP 1355921 | A2 | 20031029 | EP 2001-955795 | 20010629 <-- |

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR

| | | | | | |
|---|---|---|---|---|---|
| JP 2005520480 | T | 20050714 | JP 2002-507845 | | 20010629 <-- |
| AU 2001277854 | B2 | 20070301 | AU 2001-277854 | | 20010629 <-- |
| PRIORITY APPLN. INFO.: | | | US 2000-606628 | A2 | 20000629 <-- |
| | | | US 2001-267170P | P | 20010315 <-- |
| | | | US 2001-1 | A | 20010315 <-- |
| | | | WO 2001-US20849 | W | 20010629 <-- |

OTHER SOURCE(S): MARPAT 136:79802

AB The invention is directed to small organic mols. and peptides having the ability to mimic or agonize hepatocyte growth factor/ scatter factor (HGF/SF) activity, or inhibit or antagonize HGF/SF activity, the former useful for promoting, for example, vascularization of tissues or organs for promoting wound or tissue healing, or augmenting or restoring blood flow to ischemic tissues such as the heart following myocardial infarction. Inhibition of cellular growth or proliferation is beneficial in the treatment, for example, of inflammatory diseases such as inflammatory joint and skin diseases, and dysproliferative diseases such as cancer.

IT 320417-50-3
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peptide and small-mol. modulators of cellular proliferation and angiogenesis)

RN 320417-50-3 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-chlorophenyl)-6-(dimethylamino)-2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 9 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1995:867635 HCAPLUS Full-text

DOCUMENT NUMBER: 123:286068

ORIGINAL REFERENCE NO.: 123:51267a,51270a

TITLE: Preparation of pyrimidine derivatives

INVENTOR(S): Okada, Tetsuo; Konoike, Toshiro

PATENT ASSIGNEE(S): Shionogi Seiyaku Kk, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| JP 07118233 | A | 19950509 | JP 1993-261365 | 19931019 <-- |
| JP 3400038 | B2 | 20030428 | | |

PRIORITY APPLN. INFO.: JP 1993-261365 19931019 <--
OTHER SOURCE(S): CASREACT 123:286068; MARPAT 123:286068
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Pyrimidine derivs. I [R1 = (un)substituted alkyl, etc.; R2, R3 = H, (un)substituted alkyl, etc.; R4 = H, carboxy-protecting group; R5 = H, hydroxy-protecting group; X = N, etc.], useful as pharmaceutical intermediates, are prepared from pyrimidinecarboxaldehydes. Thus, a mixture of pyrimidine derivative II, phosphonate III (TBDMS = tert-butyldimethylsilyl), and potassium tert-butoxide in acetonitrile was stirred at room temperature for 30 min to give, after workup, 74% pyrimidine derivative IV.

IT 122930-36-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrimidine derivs.)

RN 122930-36-3 HCAPLUS

CN 5-Pyrimidinecarboxaldehyde, 4-(4-fluorophenyl)-6-methyl-2-phenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L24 ANSWER 10 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1989:553830 HCAPLUS Full-text
DOCUMENT NUMBER: 111:153830
ORIGINAL REFERENCE NO.: 111:25661a,25664a
TITLE: Pyrimidine-type mevalonolactones and related compounds, antihyperlipemic agents containing them, and their use
INVENTOR(S): Fujikawa, Yoshihiro; Iwasaki, Hiroshi; Suzuki, Mikio; Sakashita, Mitsuaki; Kitahara, Masaki
PATENT ASSIGNEE(S): Nissan Chemical Industries, Ltd., Japan
SOURCE: Eur. Pat. Appl., 63 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| EP 308736 | A2 | 19890329 | EP 1988-114705 | 19880908 <-- |
| EP 308736 | A3 | 19900214 | | |
| R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE | | | | |
| JP 01294665 | A | 19891128 | JP 1988-203381 | 19880816 <-- |
| US 5026708 | A | 19910625 | US 1988-243468 | 19880912 <-- |

WO 9010624 A1 19900920 WO 1989-JP250 19890308 <--
W: AU, DK, FI, HU, NO
AU 8932127 A 19901009 AU 1989-32127 19890308 <--
PRIORITY APPLN. INFO.: JP 1987-229357 A 19870912 <--
JP 1988-14027 A 19880125 <--
JP 1988-142695 A 19880611 <--
JP 1988-203381 A 19880816 <--
WO 1989-JP250 A 19890308 <--
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 111:153830

GI For diagram(s), see printed CA Issue.

AB Title compds. I [R1 = (un)substituted Ph; R2 = H, alkyl, alkenyl, cycloalkyl, (un)substituted Ph, Ph(CH2)m (m = 1-3), (CH2)nCHMePh or Ph(CH2)nCHMe (n = 0-2); R3 = alkyl, cycloalkyl, naphthyl, pyridyl, (un)substituted Ph, alkyl substituted by naphthyl or (un)substituted Ph and by 0-2 alkyl; Y = CH2, CH2CH2, CH:CH, CH2CH:CH, CH:CHCH2; Z = XCH2WCH2CO2R4, Q1-Q3; X = CO, C(OR8)2, CH(OH); W = CO, C(OR8)2, CR5(OH); R4 = H, physiol. hydrolyzable alkyl, NH4, Na, K, 1/2 Ca, (di- or tri)alkylammonium; R5-R7 = H, alkyl; R8 = primary or secondary alkyl; (R8)2 = (CH2)2, (CH2)3], useful as antihyperlipemics, are prepared p-FC6H4CHO was condensed with MeCOCH2CO2Et (85.2%) and then with PhC(:NH)NH2.HCl (85.0%) and the product aromatized by KMnO4 in Me2CO (32.4%) to give Et 4-(4-fluorophenyl)-6-methyl-2-phenylpyrimidine-5- carboxylate. This underwent reduction by Dibal to the alc. (90.5%), reoxidn. to the aldehyde (53.9%), Wittig reaction with (EtO)2P(O)CH2CO2Et, (93.9%), Dibal reduction (95.7%), reoxidn. with MnO2 (59.4%), condensation with MeCOCH2CO2Et using NaH (22.6%), and NaBH4 reduction (43.3%) to give ester II. Soft capsules (100) were prepared from I 1.00, PEG-400 3.89, saturated fatty acid triglyceride 15.00, peppermint oil 0.01, and Polysorbate-80 0.10 g. I were more active than both mevinolin and CS-514 in an in vitro test of cholesterol biosynthesis inhibition, and more active than the latter in cell culture and in vivo tests.

IT 122930-36-3P 122930-70-5P 122930-71-6P
122930-72-7P 122930-74-9P 122930-75-0P
122930-76-1P 122930-77-2P 122930-78-3P
122930-80-7P 122930-81-8P 122930-82-9P
122930-83-0P 122930-84-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, in preparation of antihyperlipidemic pyrimidine-containing mevalanolactones)

RN 122930-36-3 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(4-fluorophenyl)-6-methyl-2-phenyl- (CA INDEX NAME)




RN 122930-70-5 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-methyl-2,6-diphenyl- (CA INDEX NAME)



RN 122930-71-6 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 2-(4-chlorophenyl)-4-(4-fluorophenyl)-6-methyl-
(CA INDEX NAME)



RN 122930-72-7 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(3,5-dimethylphenyl)-6-methyl-2-phenyl- (CA
INDEX NAME)



RN 122930-74-9 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(4-bromophenyl)-6-methyl-2-phenyl- (CA
INDEX NAME)



RN 122930-75-0 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-phenyl-
(CA INDEX NAME)



RN 122930-76-1 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(4-fluorophenyl)-2-phenyl-6-propyl- (CA

INDEX NAME)



RN 122930-77-2 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-(4-fluorophenyl)-6-(1-methylethyl)-2-(4-methylphenyl)- (CA INDEX NAME)



RN 122930-78-3 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-cyclopropyl-6-(4-fluorophenyl)-2-phenyl- (CA INDEX NAME)



RN 122930-80-7 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 2-(3-chlorophenyl)-4-cyclopropyl-6-(4-fluorophenyl)- (CA INDEX NAME)



RN 122930-81-8 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-cyclopropyl-6-(4-fluorophenyl)-2-(4-methoxyphenyl)- (CA INDEX NAME)



RN 122930-82-9 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-cyclopropyl-6-(4-fluorophenyl)-2-(4-methylphenyl)- (CA INDEX NAME)



RN 122930-83-0 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 2-[1,1'-biphenyl]-4-yl-4-cyclopropyl-6-(4-fluorophenyl)- (CA INDEX NAME)



RN 122930-84-1 HCAPLUS
CN 5-Pyrimidinecarboxaldehyde, 4-cyclopropyl-6-(4-fluorophenyl)-2-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 11 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1970:21673 HCAPLUS Full-text
DOCUMENT NUMBER: 72:21673
ORIGINAL REFERENCE NO.: 72:3965a,3968a
TITLE: 2,5,6-Triphenyl-4-hydrazino-pyrimidine and its derivatives
AUTHOR(S): Giammanco, Lorenzo
SOURCE: Atti della Accademia di Scienze, Lettere e Arti di Palermo, Parte 1: Scienze (1968), Volume Date 1966-1967, 27, 449-63
CODEN: AASLAN; ISSN: 0365-0448
DOCUMENT TYPE: Journal
LANGUAGE: Italian
GI For diagram(s), see printed CA Issue.
AB 2,5,6-Triphenyl-4-oxopyrimidine (2 g) is refluxed 1 hr with 5 g of PCl5 and the oil crystallizes spontaneously to furnish I (X = Cl) (Ia), m. 140-2°. Ia (1.71 g) is suspended in 30 ml EtOH, 0.36 g anhydrous hydrazine is added and the solution is refluxed 3 hr to give I (X = NHNH2) (Ib), m. 200-2°. Ib (1 g) is dissolved in a cool solution of 10 ml pyridine and 10 ml Ac2O. The solution is left at room temperature 3 days to give I (X = NHNHAc), m. 75-8°. Ib (0.35 g) is dissolved in 10 ml pyridine, a few drops of BzCl added and the solution refluxed 4 hr to give I (X = NHNHBz), m. 180-2°. Ia (1.75 g) and 0.7 g isoniazid in 20 ml pyridine refluxed 40 min gives I (X = isonicotinoylhydrazinyl), m. 195°. Ib is boiled with RNCS to give the following I (R = Ph, X = NHNHCSNHR'; R' and m.p. given): Ph, 194°; Bu, 230°; CH2:CHCH2, 233-5°; Et, 243-5°. Ib (0.5 g) is dissolved in 10 ml 20% KOH and 10 ml EtOH and then 0.5 g of CS2 is added. The solution is shaken at room temperature, and after 12-13 hr and work up II, m. 195°, is obtained. KNO3 (3 g) added to 1 g Ib dissolved in 10 ml HOAc gave III, m. 137-40°. The compds. were prepared to study the pharmacol. importance of the substitution of various radicals in position 4 of the pyrimidine ring.
IT 21877-78-1P, Pyrimidine, 4-azido-2,5,6-triphenyl-
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 21877-78-1 HCAPLUS
CN Pyrimidine, 4-azido-2,5,6-triphenyl- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L24 ANSWER 12 OF 12 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1969:57761 HCAPLUS Full-text
DOCUMENT NUMBER: 70:57761
ORIGINAL REFERENCE NO.: 70:10848h,10849a
TITLE: Syntheses of heterocycles with thioacylmalononitriles
AUTHOR(S): Hartke, K.; Peshkar, L.

CORPORATE SOURCE: Univ. Marburg, Marburg-Lahn, Fed. Rep. Ger.
SOURCE: Pharmazeutische Zentralhalle (1968), 107(5), 348-55
CODEN: PHZEBE; ISSN: 0369-9781
DOCUMENT TYPE: Journal
LANGUAGE: German

AB Malononitrile was condensed with dithio and thionic acid esters of aromatic carboxylic acids to give salts of thioacylmalonic acid derivs., which can be converted to thioenol ethers. The last 2 compds. are important intermediates for a pharmaceutically interesting ring structure. Thus, 1.4 g. Me(NaS)C:C(CN)2 (Ia) was dissolved in 10 ml. absolute EtOH, treated with 1.23 g. Et chloroacetate and 1 g. Me3N for 30 min. under reflux, the solvent evaporated, and some water added to crystallize 1.72 g. 3-amino-5-methyl-2-ethoxycarbonyl-4-thiophenecarbonitrile, m. 140° (EtOH). Similarly prepared was 3-amino-5-methyl-2-benzoyl- (m. 153°) and 3-amino-5-methyl-2-cyano-4-thiophenecarbonitrile (m. 221°). In an analogous manner 3-amino-5-phenyl-2-acetyl-4-thiophenecarbonitrile, m. 171°, was obtained from Ph(HS)C:-C(CN)2. To 1.38 g. Me(MeS)C:C(CN)2 (I) in 10 ml. Et2O was added 0.46 g. MeNHNH2 to give after evaporation and recrystn. 1.25 g. 3-amino-1,5-dimethyl-4-pyrazolecarbonitrile, m. 131°. Similarly prepared were 3-amino-1-methyl-5-phenyl- (m. 158°); 5-amino-3-methyl- (m. 162°), 5-amino-1-phenyl-3-methyl- (m. 128°), and 5-amino-3-phenyl-4-pyrazolecarbonitrile (m. 201°). Also prepared was 5-amino-3-methyl-4-isoxazolecarbonitrile, m. 220° (EtOH/H2O). To 0.23 g. Na in 10 ml. absolute EtOH was added 0.96 g. guanidine-HCl, the precipitated NaCl filtered off, and 1.38 g. I added to the filtrate. The resultant 1.2 g. yellow crystals were filtered off and recrystd. to give 2,4-diamino-6-methyl-5-pyrimidinecarbonitrile, m. 292° (H2O). Similarly prepared were 4-amino-6-methyl-2-phenyl- (m. 186-7°), 4-amino-2,6-diphenyl- (m. 214.5°), and 4-amino-2-phenyl-6-benzyl-5-pyrimidinecarbo-nitrile (m. 187°). To 9.66 g. I in 100 ml. CHCl3 was added dropwise with stirring at room temperature within 30 min. 19 g. SO2Cl2. After an addnl. hr. the mixture was concentrated under vacuum and the residue fractionated to give 6.3 g. ClMeC:C(CN)2 (II), b0.11 83°. The II was converted to Me(EtO)C:C(CN)2, m. 88°. Treating Me(HS)C:C(CN)2 with COCl2 gave [(NC)2C:CMe]2S, m. 82°.

IT 20954-77-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20954-77-2 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2,6-diphenyl- (CA INDEX NAME)




=> => d stat que l30
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 12

STEREO ATTRIBUTES: NONE
L3 173813 SEA FILE=REGISTRY SSS FUL L1
L8 STR



VAR G1=5/7/9/11/16/19/CN/NO/OH/SH
VAR G2=21/22/23/24/26
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 27 25
NUMBER OF NODES IS 30

STEREO ATTRIBUTES: NONE
L15 7677 SEA FILE=REGISTRY SUB=L3 SSS FUL L8

L16 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L18 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L19 1520 SEA FILE=REGISTRY SUB=L15 SSS FUL L8 NOT (L16 OR L18)
L20 STR

NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
GGCAT IS MCY AT 2
DEFAULT ECLEVEL IS LIMITED

```
GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS   3

STEREO ATTRIBUTES: NONE
L21          338 SEA FILE=REGISTRY SUB=L19 SSS FUL L20
L22          104 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L21
L23           86 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L22 AND (AY=<2006 OR PY=<2006
                 OR PRY=<2006 OR PD=<JUNE 8, 2006)
L24           12 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23 AND (?DRUG? OR ?PHARM? OR
                 ?MEDIC? OR ?THERAP?)
L25               STR
```




```
VAR G1=5/7/9/11/16/19/CN/NO/OH/SH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC  27  25
NUMBER OF NODES IS  29

STEREO ATTRIBUTES: NONE
L26          309 SEA FILE=REGISTRY SUB=L21 SSS FUL L25
L27           95 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L26
L28           77 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L27 AND (AY=<2006 OR PY=<2006
                 OR PRY=<2006 OR PD=<JUNE 8, 2006)
L29           66 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L28 NOT L24
L30            4 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L29 AND THU/RL


=> d ibib abs hitstr l30 1-4

L30  ANSWER 1 OF 4  HCAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2003:656755  HCAPLUS  Full-text
DOCUMENT NUMBER:          139:197497
TITLE:                    Preparation of novel pyridines and pyrimidines as DPP
```

IV inhibitors
INVENTOR(S): Boehringer, Markus; Loeffler, Bernd Michael; Peters, Jens-Uwe; Steger, Matthias; Weiss, Peter
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2003068757 | A1 | 20030821 | WO 2003-EP1107 | 20030205 <-- |
| WO 2003068757 | A9 | 20041007 | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2474578 | A1 | 20030821 | CA 2003-2474578 | 20030205 <-- |
| CA 2474578 | C | 20090825 | | |
| AU 2003206833 | A1 | 20030904 | AU 2003-206833 | 20030205 <-- |
| AU 2003206833 | B2 | 20060720 | | |
| EP 1476435 | A1 | 20041117 | EP 2003-704536 | 20030205 <-- |
| EP 1476435 | B1 | 20100630 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | |
| BR 2003007665 | A | 20050104 | BR 2003-7665 | 20030205 <-- |
| CN 1630644 | A | 20050622 | CN 2003-803774 | 20030205 <-- |
| CN 1324015 | C | 20070704 | | |
| JP 2005526035 | T | 20050902 | JP 2003-567888 | 20030205 <-- |
| JP 4359146 | B2 | 20091104 | | |
| RU 2293731 | C2 | 20070220 | RU 2004-127576 | 20030205 <-- |
| AT 472536 | T | 20100715 | AT 2003-704536 | 20030205 <-- |
| US 20030216382 | A1 | 20031120 | US 2003-361268 | 20030210 <-- |
| US 6867205 | B2 | 20050315 | | |
| MX 2004007744 | A | 20041015 | MX 2004-7744 | 20040810 <-- |
| US 20050143405 | A1 | 20050630 | US 2005-37989 | 20050118 <-- |
| US 7022718 | B2 | 20060404 | | |

| PRIORITY APPLN. INFO.: | | | |
|---|---|---|---|
| | EP 2002-3114 | A | 20020213 <-- |
| | WO 2003-EP1107 | W | 20030205 <-- |
| | US 2003-361268 | A3 | 20030210 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 139:197497
GI



I



II

AB The title compds. [I; X = N, CR5; R1, R2 = H, alkyl; R3 = (un)substituted heterocyclyl or aryl; R4 = alkyl, alkoxy, alkylthio, etc.; R5 = H, alkyl], useful for the treatment and/or prophylaxis of diseases which are associated with DPP IV, such as diabetes, particularly non-insulin dependent diabetes mellitus, and impaired glucose tolerance, were prepared and formulated. Thus, reacting benzamidine with 2-(2,4-dimethylbenzylidene)malononitrile in the presence of K2CO3 in MeOH followed by treating the reaction residue with KMnO4 in Me2CO, and reduction of the resulting nitrile with LiAlH4 in THF afforded 7% II which showed IC50 of 0.172 μM against DPP IV.

IT 65112-63-2
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel pyridine and pyrimidine derivs. as DPP IV inhibitors)

RN 65112-63-2 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(methylamino)-2,6-diphenyl- (CA INDEX NAME)



IT 475995-40-5P, 4-Amino-6-(2,4-dichlorophenyl)-2-phenylpyrimidine-5-carbonitrile 582306-94-3P 582306-95-4P 582306-96-5P 582306-97-6P 582306-98-7P 582306-99-8P 582307-00-4P 582307-01-5P 582307-02-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel pyridine and pyrimidine derivs. as DPP IV inhibitors)

RN 475995-40-5 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-94-3 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-amino-2-phenyl-6-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 582306-95-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-96-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(3-methoxyphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-97-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(3-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-98-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(4-methylphenyl)-2-phenyl- (CA INDEX NAME)



RN 582306-99-8 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3-methoxyphenyl)- (CA INDEX NAME)



RN 582307-00-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-difluorophenyl)-2-phenyl- (CA INDEX NAME)



RN 582307-01-5 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3-methylphenyl)- (CA INDEX NAME)



RN 582307-02-6 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-amino-6-(2,4-dichlorophenyl)-2-(3,4,5-trimethoxyphenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2002:240780 HCAPLUS Full-text
DOCUMENT NUMBER: 136:279442
TITLE: Preparation of thienopyrimidinecarboxamides, quinazolinecarboxamides, and related compounds as luteinizing hormone agonists.
INVENTOR(S): Timmers, Cornelis Marius; Karstens, Willem Frederik Johan
PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002024703 | A1 | 20020328 | WO 2001-EP10743 | 20010917 <-- |
| W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CO, CR, CU, CZ, DM, DZ, EC, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, TJ, TM | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2422054 | A1 | 20020328 | CA 2001-2422054 | 20010917 <-- |
| AU 2002013929 | A | 20020402 | AU 2002-13929 | 20010917 <-- |
| EP 1322651 | A1 | 20030702 | EP 2001-982306 | 20010917 <-- |
| EP 1322651 | B1 | 20080123 | | |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | |
| BR 2001013987 | A | 20030812 | BR 2001-13987 | 20010917 <-- |
| HU 2003002648 | A2 | 20031128 | HU 2003-2648 | 20010917 <-- |
| HU 2003002648 | A3 | 20041129 | | |
| NZ 524444 | A | 20040326 | NZ 2001-524444 | 20010917 <-- |
| JP 2004509896 | T | 20040402 | JP 2002-529113 | 20010917 <-- |
| RU 2271360 | C2 | 20060310 | RU 2003-111463 | 20010917 <-- |
| CN 1247594 | C | 20060329 | CN 2001-816067 | 20010917 <-- |
| AU 2002213929 | B2 | 20060413 | AU 2002-213929 | 20010917 <-- |
| CZ 297136 | B6 | 20060913 | CZ 2003-828 | 20010917 <-- |
| EP 1886999 | A2 | 20080213 | EP 2007-113490 | 20010917 <-- |
| EP 1886999 | A3 | 20080312 | | |
| R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, LV, | | | | |

| | | | | | |
|---|---|---|---|---|---|
| | MC, NL, PT, SE, TR | | | | |
| AT | 384726 | T | 20080215 | AT 2001-982306 | 20010917 <-- |
| PT | 1322651 | E | 20080228 | PT 2001-982306 | 20010917 <-- |
| ES | 2299524 | T3 | 20080601 | ES 2001-982306 | 20010917 <-- |
| IL | 154624 | A | 20090901 | IL 2001-154624 | 20010917 <-- |
| TW | 290143 | B | 20071121 | TW 2001-90123098 | 20010919 <-- |
| ZA | 2003001588 | A | 20040622 | ZA 2003-1588 | 20030226 <-- |
| IN | 2003CN00394 | A | 20050408 | IN 2003-CN394 | 20030313 <-- |
| IN | 205993 | A1 | 20070629 | | |
| MX | 2003002478 | A | 20040505 | MX 2003-2478 | 20030320 <-- |
| NO | 2003001314 | A | 20030321 | NO 2003-1314 | 20030321 <-- |
| NO | 328683 | B1 | 20100426 | | |
| HR | 2003000220 | A2 | 20030630 | HR 2003-220 | 20030321 <-- |
| US | 20030225113 | A1 | 20031204 | US 2003-381248 | 20030321 <-- |
| US | 7229990 | B2 | 20070612 | | |
| KR | 860040 | B1 | 20080925 | KR 2003-704132 | 20030321 <-- |
| HK | 1054942 | A1 | 20080403 | HK 2003-107319 | 20031013 <-- |
| US | 20070197527 | A1 | 20070823 | US 2007-788886 | 20070423 <-- |
| US | 7618963 | B2 | 20091117 | | |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| EP 2000-203287 | A | 20000922 <-- |
| EP 2001-982306 | A3 | 20010917 <-- |
| WO 2001-EP10743 | W | 20010917 <-- |
| US 2003-381248 | A1 | 20030321 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:279442

GI



I

AB Title compds. [I; R1 = (substituted) cycloalkyl, heterocycloalkyl, aryl, heteroaryl; R2 = alkyl, alkenyl, alkynyl, aryl, heteroaryl; R3 = alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl; Y = CH, N; Z = NH2, OH; A = S, NH, NR, O, bond; B = NH, O, bond; X1-X2 = C:C, CONH, CO2, C:N, S, O], were prepared Thus, S-methylisothiourea sulfate, 3-MeOC6H4CHO, EtO2CCH2CN, and K2CO3 were stirred 5 h at 60° in EtOH to give 5-cyano-4-(3-methoxyphenyl)-2-methylthio-6-hydroxypyrimidine. This was stirred with POCl3 and PhNMe2 in dioxane at 80° for 3 h to give 6-chloro-5-cyano-4-(3-methoxyphenyl)-2-methylthiopyrimidine. The latter was stirred with KOCMe3 and EtO2CCH2SH in THF for 1 h to give Et 5-amino-4-(3-methoxyphenyl)-2-methylthiothieno[2,3-d]pyrimidine-6- carboxylate. This was converted to title compound tert-Bu 5-amino-2-methylthio-4-(3-methoxycarbonyloxy)phenylthieno[2,3-d]pyrimidine- 6-carboxamide in several steps. Several I stimulated human LH receptors in CHO cells with IC50 = 10-7 to 10-8 M.

IT 405891-46-5P 405891-47-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of thienopyrimidinecarboxamides, quinazolinecarboxamides, and related compds. as LH agonists)

RN 405891-46-5 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-chloro-6-(3-nitrophenyl)-2-phenyl- (CA INDEX

NAME)



RN 405891-47-6 HCAPLUS
CN Acetic acid, 2-[[5-cyano-6-(3-nitrophenyl)-2-phenyl-4-pyrimidinyl]thio]-, ethyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 1989:135258 HCAPLUS Full-text
DOCUMENT NUMBER: 110:135258
ORIGINAL REFERENCE NO.: 110:22338h,22339a
TITLE: Preparation of (2,6-disubstituted-5-cyano-4-pyrimidinyloxy)acetic acid as aldose reductase inhibitors
INVENTOR(S): Bagli, Jehan F.; Ellingboe, John W.; Alessi, Thomas R.
PATENT ASSIGNEE(S): American Home Products Corp., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| US 4786640 | A | 19881122 | US 1987-62734 | 19870612 <-- |
| US 4906753 | A | 19900306 | US 1988-221586 | 19880720 <-- |
| PRIORITY APPLN. INFO.: | | | US 1987-62734 A3 | 19870612 <-- |

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 110:135258; MARPAT 110:135258
GI



AB The title compds. [I; R1 = C1-6 alkyl, C3-6 cycloalkyl, (halo-substituted) Ph, phenylmethyl, (halo-substituted) naphthalenyl, thienyl; R = SR2 (wherein R2 = C1-6 alkyl, C4-7 cycloalkylmethyl, phenylmethyl optionally substituted by halo), C1-4 alkyl, Ph, 1-naphthalenylmethyl], useful as aldose reductase inhibitors, were prepared To a cooled (0°), stirred suspension of NaH in DMF was added a solution of 0.025 mol Me3CC(:NH)OMe.HCl (prepared from Me3CCN, AcCl, and MeOH). The mixture was stirred at room temperature for 1 h and then cooled to 0°. A solution of 0.022 mol 3.3-bis(cyclohexylmethylthio)-2-cyano-2-propenoate [prepared from (KS)2C:C(CN)CO2Me and (bromomethyl)cyclohexane was added dropwise. The resulting mixture was stirred 1 h at room temperature overnight to give 71% 4-[(cyclohexylmethyl)thio]-1,6-dihydro-2-(1,1-dimethylethyl)-6-oxo-5- pyrimidinecarbonitrile which was alkylated by BrCH2CO2CMe3 in DMF containing NaH to give 92% tert-Bu [[5-cyano-6-[(cyclohexylmethyl)thio]-2-(tert- butyl)-4-pyrimidinyl]oxy]acetate. Treatment of the latter with CF3CO2H gave 40% I [R = (cyclohexylmethyl)thio, R1 = Me3C] (II) which at 10-5M inhibited 97% aldose reductase in vitro.

IT 119491-88-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as aldose reductase inhibitor)

RN 119491-88-2 HCAPLUS

CN Acetic acid, 2-[(5-cyano-2,6-diphenyl-4-pyrimidinyl)oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L30 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 1979:137763 HCAPLUS Full-text

DOCUMENT NUMBER: 90:137763

ORIGINAL REFERENCE NO.: 90:21845a,21848a

TITLE: Synthesis of 2,6,9-trisubstituted 7H-purin-8-ones

AUTHOR(S): Robev, S.

CORPORATE SOURCE: Med. Fak., Sofia, Bulg.

SOURCE: Doklady Bolgarskoi Akademii Nauk (1978), 31(9), 1131-4
CODEN: DBANAD; ISSN: 0366-8681

DOCUMENT TYPE: Journal

LANGUAGE: Russian

OTHER SOURCE(S): CASREACT 90:137763

GI



I



II

AB The title compds. I [R1 = (un)substituted Ph, R2 = (un)substituted Ph, 2-naphthyl; R3 = (un)substituted Ph, 1- or 2-naphthyl, 2-pyridyl] were prepared in 42-90 % yields from pyrimidinecarbonitriles II by hydration with polyphosphoric acid followed by cyclization in the presence of NaOCl-KOH. I (R1 = R2 = R3 = Ph, R1 = Ph, R2 = 4-FC6H4, R3 = 4-MeC6H4) are effective as inhibitors of Sarcoma-180 Kroker in mice at 180 mg/kg and 150 mg/kg, resp.

IT 64499-00-9 64499-01-0 64499-32-7
64530-27-4 67677-96-7 67677-97-8
69728-70-7 69728-84-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(hydration of)

RN 64499-00-9 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(1-naphthalenyl)-2-phenyl-6-(phenylamino)- (CA INDEX NAME)



RN 64499-01-0 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(2-naphthalenyl)-2-phenyl-6-(phenylamino)- (CA INDEX NAME)



RN 64499-32-7 HCAPLUS

CN 5-Pyrimidinecarbonitrile, 4-(4-methylphenyl)-2-phenyl-6-(phenylamino)- (CA INDEX NAME)



RN 64530-27-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[(2-methylphenyl)amino]-2,6-diphenyl- (CA INDEX NAME)



RN 67677-96-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 2,4-diphenyl-6-(phenylamino)- (CA INDEX NAME)



RN 67677-97-8 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(4-bromophenyl)-2-phenyl-6-(phenylamino)- (CA INDEX NAME)



RN 69728-70-7 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(2,4-dimethylphenyl)-6-[(4-methylphenyl)amino]-2-phenyl- (CA INDEX NAME)



RN 69728-84-3 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-[(4-bromophenyl)amino]-6-(2-naphthalenyl)-2-phenyl- (CA INDEX NAME)



IT 69728-71-8P 69728-72-9P 69728-83-2P
69728-85-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and hydration of)
RN 69728-71-8 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 2-[4-(dimethylamino)phenyl]-4-(4-methylphenyl)-6-(phenylamino)- (CA INDEX NAME)



RN 69728-72-9 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-bromophenyl)-4-(2-naphthalenyl)-6-(phenylamino)- (CA INDEX NAME)



RN 69728-83-2 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 4-(3-bromophenyl)-6-[(4-chlorophenyl)amino]-2-phenyl- (CA INDEX NAME)



RN 69728-85-4 HCAPLUS
CN 5-Pyrimidinecarbonitrile, 2-(4-fluorophenyl)-4-(4-methylphenyl)-6-(phenylamino)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

```
=> d his nofile

     (FILE 'REGISTRY' ENTERED AT 09:50:19 ON 14 AUG 2010)
L1             STR
L3          173813 SEA SSS FUL L1
L8             STR
L15           7677 SEA SUB=L3 SSS FUL L8
L16            STR
L18            STR
L19           1520 SEA SUB=L15 SSS FUL L8 NOT (L16 OR L18)
L20            STR
L21            338 SEA SUB=L19 SSS FUL L20

     FILE 'HCAPLUS' ENTERED AT 10:22:56 ON 14 AUG 2010
L22            104 SEA ABB=ON  PLU=ON  L21
L23             86 SEA ABB=ON  PLU=ON  L22 AND (AY=<2006 OR PY=<2006 OR PRY=<2006
                   OR PD=<JUNE 8, 2006)
L24             12 SEA ABB=ON  PLU=ON  L23 AND (?DRUG? OR ?PHARM? OR ?MEDIC? OR
                   ?THERAP?)
                   D STAT QUE L24
                   D IBIB ABS HITSTR L24 1-12

     FILE 'REGISTRY' ENTERED AT 10:28:20 ON 14 AUG 2010
L25            STR L8
L26            309 SEA SUB=L21 SSS FUL L25

     FILE 'HCAPLUS' ENTERED AT 10:29:47 ON 14 AUG 2010
L27             95 SEA ABB=ON  PLU=ON  L26
L28             77 SEA ABB=ON  PLU=ON  L27 AND (AY=<2006 OR PY=<2006 OR PRY=<2006
                   OR PD=<JUNE 8, 2006)
L29             66 SEA ABB=ON  PLU=ON  L28 NOT L24
L30              4 SEA ABB=ON  PLU=ON  L29 AND THU/RL
                   D STAT QUE L30
                   D IBIB ABS HITSTR L30 1-4

=>
```